Nothing Special   »   [go: up one dir, main page]

HUE044747T2 - Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására - Google Patents

Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására

Info

Publication number
HUE044747T2
HUE044747T2 HUE14781761A HUE044747T2 HU E044747 T2 HUE044747 T2 HU E044747T2 HU E14781761 A HUE14781761 A HU E14781761A HU E044747 T2 HUE044747 T2 HU E044747T2
Authority
HU
Hungary
Prior art keywords
generating
light chain
same
genetically modified
chain antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/030,424 external-priority patent/US20140013456A1/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUE044747T2 publication Critical patent/HUE044747T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE14781761 2013-09-18 2014-09-18 Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására HUE044747T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/030,424 US20140013456A1 (en) 2012-03-16 2013-09-18 Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same

Publications (1)

Publication Number Publication Date
HUE044747T2 true HUE044747T2 (hu) 2019-11-28

Family

ID=51663490

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14781761 HUE044747T2 (hu) 2013-09-18 2014-09-18 Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására

Country Status (25)

Country Link
EP (2) EP3046412B1 (hu)
JP (3) JP6621750B2 (hu)
KR (2) KR102150414B1 (hu)
CN (2) CN105722387B (hu)
AU (2) AU2014323527B2 (hu)
BR (1) BR112016005912A2 (hu)
CA (1) CA2922892C (hu)
CY (1) CY1121798T1 (hu)
DK (1) DK3046412T3 (hu)
ES (2) ES2738679T3 (hu)
HK (1) HK1225913A1 (hu)
HR (1) HRP20191233T1 (hu)
HU (1) HUE044747T2 (hu)
IL (2) IL244226B (hu)
LT (1) LT3046412T (hu)
MX (1) MX362904B (hu)
MY (1) MY191512A (hu)
PL (1) PL3046412T3 (hu)
PT (1) PT3046412T (hu)
RS (1) RS59003B1 (hu)
RU (2) RU2019121863A (hu)
SG (2) SG11201601272YA (hu)
SI (1) SI3046412T1 (hu)
TR (1) TR201909967T4 (hu)
WO (1) WO2015042250A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN113416257A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
MX2015014017A (es) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Variante de la region fc.
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
WO2020132557A1 (en) * 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
JP2023508290A (ja) * 2019-12-18 2023-03-02 ブリストル-マイヤーズ スクイブ カンパニー 共通のリーダー配列を有するbcrトランスジェニックマウス
WO2022056276A1 (en) 2020-09-11 2022-03-17 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114568343B (zh) * 2022-03-11 2023-04-07 成都合拓创展生物科技有限公司 制备眼病模型的头具及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
BRPI0712224B8 (pt) 2006-06-02 2021-05-25 Regeneron Pharma anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
TR201808046T4 (tr) * 2008-04-11 2018-06-21 Chugai Pharmaceutical Co Ltd İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
AU2009313389A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
DE112010002931T5 (de) 2009-07-16 2012-08-30 Wageningen Universiteit Regulierung von Zinkmangel und Zinktoleranz bei Pflanzen
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US20130096281A1 (en) * 2010-01-21 2013-04-18 Oxyrane Uk Limited Methods and compositions for displaying a polypeptide on a yeast cell surface
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR101829691B1 (ko) 2010-02-08 2018-02-19 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CA2792740A1 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation Antibodies with ph dependent antigen binding
SI3034608T1 (sl) * 2010-06-22 2019-06-28 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo hibridno lahko verigo imunoglobulina s humano variabilno regijo
US8367586B2 (en) * 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
EP3778889A1 (en) * 2011-09-30 2021-02-17 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
US20140013456A1 (en) * 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2017114166A (ru) * 2013-02-20 2019-01-29 Регенерон Фармасьютикалс, Инк. Не являющиеся человеком животные с модифицированными последовательностями тяжелых цепей иммуноглобулинов

Also Published As

Publication number Publication date
WO2015042250A1 (en) 2015-03-26
TR201909967T4 (tr) 2019-07-22
DK3046412T3 (da) 2019-07-15
IL244226B (en) 2019-02-28
SG11201601272YA (en) 2016-03-30
MX2016003638A (es) 2016-07-21
EP3046412B1 (en) 2019-04-10
EP3046412A1 (en) 2016-07-27
RS59003B1 (sr) 2019-08-30
KR20160049018A (ko) 2016-05-04
IL244226A0 (en) 2016-04-21
EP3549437B1 (en) 2023-10-25
ES2738679T3 (es) 2020-01-24
SI3046412T1 (sl) 2019-08-30
CA2922892A1 (en) 2015-03-26
HRP20191233T1 (hr) 2019-10-18
CN105722387A (zh) 2016-06-29
RU2016114306A (ru) 2017-10-23
SG10201810825YA (en) 2019-01-30
EP3549437A1 (en) 2019-10-09
AU2014323527A1 (en) 2016-04-07
AU2014323527B2 (en) 2020-10-15
JP6621750B2 (ja) 2019-12-18
BR112016005912A2 (pt) 2017-09-26
RU2694728C2 (ru) 2019-07-16
MY191512A (en) 2022-06-28
LT3046412T (lt) 2019-07-25
RU2019121863A (ru) 2019-08-29
WO2015042250A4 (en) 2015-05-28
JP2016533768A (ja) 2016-11-04
KR102150414B1 (ko) 2020-09-02
AU2021200228A1 (en) 2021-03-18
EP3549437C0 (en) 2023-10-25
RU2016114306A3 (hu) 2018-04-26
CN105722387B (zh) 2020-01-17
MX362904B (es) 2019-02-25
ES2962489T3 (es) 2024-03-19
HK1225913A1 (zh) 2017-09-22
KR20200103882A (ko) 2020-09-02
PL3046412T3 (pl) 2019-11-29
PT3046412T (pt) 2019-07-16
IL264358A (en) 2019-02-28
CN111019953A (zh) 2020-04-17
CA2922892C (en) 2022-06-14
CY1121798T1 (el) 2020-07-31
JP2020078350A (ja) 2020-05-28
JP2019068850A (ja) 2019-05-09
WO2015042250A9 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
IL282452B (en) Histidine-engineered light chain antibodies, and non-human animals genetically modified for their preparation
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
HK1258227A1 (zh) 具有修飾的免疫球蛋白重鏈序列的非人類動物